Botox, Dysport, Xeomin, Jeuveau and Daxxify Units Explained
Injectors frequently search for a Botox-to-Dysport conversion, especially when transitioning between neurotoxin brands.
But there is an important clinical point to understand before looking at any conversion chart:
Botulinum toxin units are product-specific and are not officially interchangeable between brands.
Botox Cosmetic, Dysport, Xeomin, Jeuveau, and Daxxify are all botulinum toxin type A products, but their units are based on each manufacturer’s specific biological assay.
This means a “unit” should not be treated as a universal measurement like a milligram or milliliter.
Is There an Official Botox-to-Dysport Conversion Ratio?
No universally accepted FDA-approved conversion ratio exists.
This distinction matters because simplified charts can create the impression that clinicians can automatically substitute one product for another using basic arithmetic.
Product labeling instead emphasizes product-specific dosing.
For example, FDA labeling for Daxxify explicitly states that its potency units are specific to its preparation and assay method and cannot be compared with or converted into units of other botulinum toxin products. FDA Access Data
Similar product-specific principles apply when clinicians evaluate other botulinum toxin formulations.
Why Neurotoxin Units Are Different
Each manufacturer establishes potency through its own assay and manufacturing process.
Differences among products may involve formulation, potency testing, approved dosing, reconstitution instructions, diffusion characteristics, clinical evidence, and labeled indications.
Consequently, clinicians should think in terms of product-specific dosing, not simply “Botox-equivalent units.”
Botox Cosmetic
Botox Cosmetic is the brand name for onabotulinumtoxinA.
Its dosing recommendations are expressed specifically in Botox units and vary according to the approved treatment area.
Dysport
Dysport contains abobotulinumtoxinA.
Clinicians will often encounter informal Botox-to-Dysport ratios in aesthetic discussions. These may reflect clinical practice patterns or published research, but they should not be interpreted as a manufacturer-approved universal conversion formula.
Xeomin
Xeomin contains incobotulinumtoxinA.
It has its own labeled dosing and preparation instructions. Even where clinicians use similar numerical dosing in particular applications, that does not make Xeomin and Botox units formally interchangeable.
Jeuveau
Jeuveau contains prabotulinumtoxinA-xvfs and is another botulinum toxin type A formulation used for aesthetic treatment.
Its dosing should likewise follow its own prescribing information and clinical considerations.
Daxxify
Daxxify contains daxibotulinumtoxinA-lanm.
Daxxify is especially useful for illustrating why simple conversion tables can be misleading. Its prescribing information specifically states that its potency units cannot be compared to or converted into units of other botulinum toxin products. FDA Access Data
Neurotoxin Comparison at a Glance
| Product | Active Ingredient | Can Units Be Officially Converted to Botox Units? |
| Botox Cosmetic | OnabotulinumtoxinA | Reference product itself |
| Dysport | AbobotulinumtoxinA | No universal official conversion |
| Xeomin | IncobotulinumtoxinA | No |
| Jeuveau | PrabotulinumtoxinA-xvfs | No |
| Daxxify | DaxibotulinumtoxinA-lanm | No |
The safest takeaway is simple: do not assume that the number printed beside one neurotoxin brand represents the same biological activity as the same number for another.
Why Informal Conversion Ratios Still Exist
Experienced injectors may develop practical approaches when moving between products. Published studies and clinical experience have also explored dose relationships between different toxins.
That is useful clinical literature but it is different from an official interchangeable-unit system.
Treatment decisions should consider the specific product, indication, treatment area, patient anatomy, muscle strength, previous response, medical history, and applicable prescribing information.
A fixed ratio cannot account for all of those variables.
Why This Matters for New Injectors
Memorizing a conversion chart is not a substitute for understanding neurotoxin pharmacology and facial anatomy.
An injector should know:
- which product is being administered;
- its current prescribing information;
- appropriate reconstitution and handling;
- anatomy of the treatment area;
- product-specific dosing;
- contraindications and warnings; and
- how to recognize and respond to complications.
Botulinum toxin products also carry important safety warnings, including the possibility of toxin effects spreading beyond the injection site.
Learn Neurotoxins as Products, Not Just Numbers
A strong injector does more than memorize how many units are commonly placed in an area.
Clinical education should build an understanding of why a dose is selected, how anatomy changes treatment planning, and how the chosen neurotoxin behaves.
That becomes particularly important when a practice carries multiple toxin brands.
Injector Training Academy’s Botox training courses focus on anatomy, assessment, treatment planning, injection principles, and safety so healthcare professionals can build a stronger clinical foundation.
Hands-on programs are also available in Dallas, Fort Worth, Plano, Austin, Colleyville, Argyle, and Waxahachie, Texas. For clinicians expanding into men’s health, the Academy also offers penile injections training.
Continue learning through our Botox course and complications training resources to strengthen your understanding of safe neurotoxin practice.
Written by Kiara DeWitt, BSN, RN, CPN
This article is for professional education and does not provide patient-specific dosing instructions. Clinicians should use current FDA-approved prescribing information, applicable laws, their professional scope, and appropriate clinical judgment.
